CHP-212Homo sapiens (Human)Cancer cell line

Also known as: Children's Hospital of Philadelphia-212, NB-9, NB9, CHP212, CHP 212

🤖 AI SummaryBased on 14 publications

Quick Overview

Human neuroblastoma cell line with MYCN amplification and chromosomal abnormalities.

Detailed Summary

CHP-212 is a human neuroblastoma cell line derived from a pediatric tumor. It exhibits MYCN amplification, a common genetic alteration in high-risk neuroblastoma cases. The cell line shows chromosomal abnormalities, including deletions and rearrangements, which are frequently observed in neuroblastoma. These genetic features make CHP-212 a valuable model for studying the molecular mechanisms underlying neuroblastoma progression and for testing therapeutic strategies targeting MYCN-driven tumors. Research on CHP-212 has contributed to understanding the role of chromosomal instability in cancer development and the identification of potential therapeutic targets.

Research Applications

MYCN amplification studiesChromosomal instability analysisTherapeutic target identification

Key Characteristics

MYCN amplificationChromosomal abnormalitiesNeuroblastoma model
Generated on 6/16/2025

Basic Information

Database IDCVCL_1125
SpeciesHomo sapiens (Human)
Tissue SourceBrain[UBERON:UBERON_0000955]

Donor Information

Age1
Age CategoryPediatric
SexMale
Subtype FeaturesMYC_Amplified

Disease Information

DiseaseNeuroblastoma
LineagePeripheral Nervous System
SubtypeNeuroblastoma
OncoTree CodeNBL

DepMap Information

Source TypeATCC
Source IDACH-000120_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleNRASp.Gln61Lys (c.181C>A)UnspecifiedAcquired during resistance selection processPubMed=26214590

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X,Y
CSF1PO
12
D13S317
8
D16S539
13
D18S51
14,16
D19S433
12,15
D21S11
27,29
D2S1338
22,25
D3S1358
15,17
D5S818
10,12
D7S820
11
D8S1179
11,13
FGA
20
Penta D
9,10
Penta E
5,15
TH01
6
TPOX
8,11
vWA
15,18
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Intercellular extrachromosomal DNA copy-number heterogeneity drives neuroblastoma cell state diversity.

Henssen A.G., Schwarz R.F., Haase K.

Cell Rep. 43:114711.1-114711.19(2024).

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Nature 568:511-516(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines.

Hart L.S., Dent M.H., Fortina P., Reynolds C.P., Maris J.M.

Sci. Data 4:170033-170033(2017).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

Identification of ALK as a major familial neuroblastoma predisposition gene.

Maris J.M.

Nature 455:930-935(2008).

High-resolution detection and mapping of genomic DNA alterations in neuroblastoma.

Maris J.M.

Genes Chromosomes Cancer 43:390-403(2005).

Characteristics of stem cells from human neuroblastoma cell lines and in tumors.

Biedler J.L., Cheung N.-K.V., Ross R.A.

Neoplasia 6:838-845(2004).

Mutations of the BRAF gene in human cancer.";

Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.

Nature 417:949-954(2002).

Abnormalities of chromosome 1p in human neuroblastoma tumors and cell lines.

Schlesinger H.R.

Cancer Genet. Cytogenet. 7:33-42(1982).

Neuronal properties of neuroectodermal tumors in vitro.";

Schlesinger H.R., Rorke-Adams L.B., Jamieson R., Hummeler K.

Cancer Res. 41:2573-2575(1981).

Tumor cell lines of the peripheral nervous system.";

Israel M.A., Thiele C.J.

(In book chapter) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.43-78; Academic Press; New York; USA (1994).

Homogeneously staining regions and double minute chromosomes, prevalent cytogenetic abnormalities of human neuroblastoma cells.

Biedler J.L., Meyers M.B., Spengler B.A.

(In book chapter) Advances in cellular neurobiology, Vol. 4; Fedoroff S., Hertz L. (eds.); pp.267-307; Academic Press; New York; USA (1983).

Neuroblastoma.";

Thiele C.J.

(In book chapter) Human cell culture. Vol. 1. Cancer cell lines part 1; Masters J.R.W., Palsson B.O. (eds.); pp.21-53; Kluwer Academic Publishers; New York; USA (1999).